F. MHRA Actions, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA

Upon receipt of a serious breach notification, the MHRA will review and assess the notification, and a variety of actions may be taken, depending on the nature of the breach and its potential impact. In general:

1. The GCP Inspectorate checks the serious breach mailbox.

2. Receipt of the notification will be sent and a GCP Inspector will be assigned to review.

3. The Inspector is responsible for reviewing the serious breach.

4. The inspector will decide if:

  • the referral only requires to be logged with no further action (the case may be examined during future MHRA inspections).
  • further information/investigation/CAPA is required. If insufficient information is provided in the initial notification to assess the impact of the breach, follow-up information will be requested.
  • if any other bodies are required to be notified (for example, other competent authorities/EMA, Licensing Division, Clinical Trials Unit (CTU), HRA, Research Ethics Committees, other GxP areas, etc.).
  • further actions are required (for example, a referral to the MHRA Inspection Action Group if the issue is critical or trigger an inspection to investigate further).
  • referral to CTU for consideration of suspension or termination of a clinical trial authorisation.
  • referral to the MHRA Enforcement Unit for consideration of enforcement action, for example, infringement notices, criminal investigation.
  • referral to professional bodies, for example, the General Medical Council.
     

5. Once any/all required actions have been satisfactorily completed, the inspector will close the referral.

 

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

Clinical Research News

Studie der Radiological Society of North America: Genikuläre Arterienembolisation lindert Kniearthrose-Schmerzen für 12 Monate
GLP-1 und Fruchtbarkeit: Warum Medikamente zur Gewichtsreduktion in der Reproduktionsmedizin diskutiert werden
Hohes Lp(a): Neue Studie prüft Medikamentenkombination gegen erbliches Herzrisiko
Gewichtsverlust-Medikamente mit geringerem Risiko für bestimmte Krebsarten in Verbindung gebracht: Was die neuen Daten zeigen
Nach Schlaganfall und Hirnblutung: Neue Studie prüft, wann Antikoagulanzien nötig sind
Erster KI-entwickelter Impfstoff schließt klinische Studie am Menschen ab
Blut im Urin und Tumorverdacht: Neuer Urintest wird mit Zystoskopie und Biopsie verglichen

Bevorstehende klinische Studien

Clinical Research Jobs

More jobs

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

Abonnieren